Follow
Junxian Geng
Junxian Geng
Boehringer Ingelheim
Verified email at stat.fsu.edu
Title
Cited by
Cited by
Year
Probabilistic community detection with unknown number of communities
J Geng, A Bhattacharya, D Pati
Journal of the American Statistical Association, 1-13, 2018
782018
Bayesian spatial homogeneity pursuit of functional data: an application to the us income distribution
G Hu, J Geng, Y Xue, H Sang
Bayesian Analysis 18 (2), 579-605, 2023
232023
Bayesian nonparametric nonhomogeneous Poisson process with applications to USGS earthquake data
J Geng, W Shi, G Hu
Spatial Statistics 41, 100495, 2021
192021
Heterogeneity Learning for SIRS model: an Application to the COVID-19
G Hu, J Geng
Statistics and Its Interface, 2020
152020
The MDM2–p53 antagonist brigimadlin (BI 907828) in patients with advanced or metastatic solid tumors: results of a phase Ia, first-in-human, dose-escalation study
P LoRusso, N Yamamoto, MR Patel, SA Laurie, TM Bauer, J Geng, ...
Cancer Discovery 13 (8), 1802-1813, 2023
142023
A phase I dose-escalation study of the MDM2-p53 antagonist BI 907828 in patients (pts) with advanced solid tumors.
P LoRusso, MM Gounder, MR Patel, N Yamamoto, TM Bauer, S Laurie, ...
Journal of Clinical Oncology 39 (15_suppl), 3016-3016, 2021
102021
A phase Ia/Ib, dose-escalation/expansion study of the MDM2–p53 antagonist BI 907828 in patients with solid tumors, including advanced/metastatic liposarcoma (LPS)
MM Gounder, N Yamamoto, MR Patel, TM Bauer, P Schöffski, R Grempler, ...
J Clin Oncol 40 (16_suppl), 3004-4, 2022
92022
Efficacy and safety of the MDM2–p53 antagonist BI 907828 in patients with advanced biliary tract cancer: Data from two phase Ia/Ib dose-escalation/expansion trials
N Yamamoto, AW Tolcher, N Hafez, I Lugowska, R Ramlau, MM Gounder, ...
J. Clin. Oncol 41, 543, 2023
42023
A phase I, open-label, dose-escalation trial of BI 764532, a DLL3/CD3 bispecific antibody, in patients (pts) with small cell lung carcinoma (SCLC) or other neuroendocrine …
M Wermke, E Felip, V Gambardella, Y Kuboki, D Morgensztern, ...
Journal of Clinical Oncology 39 (15_suppl), TPS8588-TPS8588, 2021
42021
Mixture of finite mixtures model for basket trial
J Geng, G Hu
arXiv preprint arXiv:2011.04135, 2020
42020
A phase Ia/Ib, dose-escalation/expansion study of the MDM2–p53 antagonist BI 907828 in patients (pts) with solid tumors: Safety and efficacy in patients with dedifferentiated …
P LoRusso, MM Gounder, N Yamamoto, MR Patel, TM Bauer, J Geng, ...
Journal of Clinical Oncology 41 (16_suppl), 11554-11554, 2023
32023
A phase Ia/Ib, dose-escalation/expansion study of BI 907828 in combination with BI 754091 (ezabenlimab) and BI 754111 in patients (pts) with advanced solid tumors.
N Yamamoto, N Hafez, AW Tolcher, M Teufel, J Geng, L Svensson, ...
Journal of Clinical Oncology 40 (16_suppl), 3095-3095, 2022
32022
A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (MDM2-p53 antagonist) in adult patients with advanced or metastatic solid tumors.
CR Chong, TM Bauer, SA Laurie, MR Patel, N Yamamoto, T Davenport, ...
Journal of Clinical Oncology 37 (15_suppl), TPS3166-TPS3166, 2019
32019
452O A phase I dose-escalation and expansion study evaluating the safety and efficacy of the MDM2–p53 antagonist BI 907828 in patients (pts) with solid tumours
P Schoeffski, N Yamamoto, T Bauer, M Patel, MM Gounder, J Geng, ...
Annals of Oncology 33, S743, 2022
22022
Discovery among binary biomarkers in heterogeneous populations
J Geng, EH Slate
Statistical Modeling in Biomedical Research: Contemporary Topics and Voices …, 2020
22020
1548P A phase Ia/Ib, dose-escalation/expansion study of the MDM2–p53 antagonist BI 907828 in patients (pts) with advanced/metastatic sarcoma
M Gounder, MR Patel, N Yamamoto, TM Bauer, S Laurie, A Perez-Pitarch, ...
Annals of Oncology 32, S1124-S1125, 2021
12021
Bayesian models for capturing heterogeneity in discrete data
J Geng
The Florida State University, 2017
12017
Efficacy and safety of brigimadlin (BI 907828), an MDM2–p53 antagonist, in patients (pts) with advanced biliary tract cancer: Data from two phase Ia/Ib dose-escalation …
T Macarulla, N Yamamoto, AW Tolcher, N Hafez, I Lugowska, R Ramlau, ...
Journal of Clinical Oncology 42 (3_suppl), 487-487, 2024
2024
Longitudinal mutational analysis of TP53 in plasma circulating tumor DNA (ctDNA) in patients (pts) with solid tumors in a phase I study of BI 907828, an MDM2–p53 …
A Peltzer, R Hesse, MM Gounder, N Yamamoto, MR Patel, S Laurie, ...
Journal of Clinical Oncology 41 (16_suppl), 3036-3036, 2023
2023
42O A phase Ia/b, dose-escalation and expansion study evaluating the MDM2–p53 antagonist BI 907828 in patients with solid tumours: Safety and efficacy in patients with …
P Schoeffski, N Yamamoto, T Bauer, M Patel, P Lorusso, M Lahmar, ...
ESMO Open 8 (1), 2023
2023
The system can't perform the operation now. Try again later.
Articles 1–20